Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperimmune vaccine plasma for early COVID-19 treatment
RBR-2ggx7smNot yet recruiting
- Sponsor
- Ministério da Ciência, Tecnologia e Inovações
- Start
- Jan 2022
- Countries
- 1
01
Overview
Randomised, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ministério da Ciência, Tecnologia e Inovações. Primary endpoint: Hospitalization. Planned start Jan 2022; status: not yet recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-2ggx7sm.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2ggx7sm.